Zymeworks Inc. ZYME
26.14 USD -0.72 (-2.68%)
Regular-session close
26.14 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
26.09 Day range 27.56
21.52 52-week range 31.97
- YTD
- -0.72%
- 1 year
- +9.74%
News
globenewswire.com Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…
defenseworld.net Zymeworks (NASDAQ:ZYME) Shares Gap Up Following Analyst Upgrade Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) shares gapped up prior to trading on Monday after Citizens Jmp raised their price target on the stock from $32.00 to $39.00. The stock had previously…
globenewswire.com Zymeworks Announces $200 Million Share Repurchase Authorization Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market…benzinga.com Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39 Citizens analyst Reni Benjamin maintains Zymeworks (NASDAQ:ZYME) with a Market Outperform and raises the price target from $32 to $39.
benzinga.com Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44 Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $39 to $44.
benzinga.com TD Cowen Maintains Buy on Zymeworks, Raises Price Target to $39 TD Cowen analyst Yaron Werber maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $39.
benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $35 to $36.
benzinga.com HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $56 HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $55 to $56.
benzinga.com Zymeworks Raises FY2026 Sales Guidance from $278.000M-$292.000M to $337.000M-$351.000M vs $302.672M Est Zymeworks (NASDAQ:ZYME) raises FY2026 sales outlook from $278.000 million-$292.000 million to $337.000 million-$351.000 million vs $302.672 million estimate.
benzinga.com Zymeworks Q3 EPS $2.28 Beats $2.18 Estimate, Sales $256.460M Beat $228.465M Estimate Zymeworks (NASDAQ:ZYME) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $2.18 by 4.59 percent. This is a 976.92 percent increase over losses of $(0.26) per…
benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.
benzinga.com Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’sZymeworks will conduct the Phase 1a monotherapy…
